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BACKGROUND: To prove a causal link between an epigenetic change and an environmental or behavioural risk factor for a given
disease, it is first necessary to show that the onset of exposure precedes the first detection of that epigenetic change in subjects who
are still free of disease.
METHODS: Towards this end, a cohort of women aged 15–19 years, recruited soon after they first had sexual intercourse, were used
to provide sequential observations on the relationship between cigarette smoking and the detection in cervical cytological samples of
methylated forms of CDKN2A (p16) using nested methylation-specific polymerase chain reaction.
RESULTS: Among women who remained cytologically normal and who tested negative for human papillomavirus DNA in cervical
smears during follow-up, those who first started to smoke during follow-up had an increased risk of acquiring CDKN2A methylation
compared with never-smokers (odds ratio¼3.67; 95% confidence interval 1.09–12.33; P¼0.04).
CONCLUSION: Smoking initiation is associated with the appearance of methylated forms of CDKN2A.
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Exposure to certain behavioural and environmental factors during
critical periods of development may result in persistent epigenetic
changes, which have phenotypic consequences. For example, in
humans, cross-sectional studies suggest that prenatal exposure
to famine, in utero exposure to airborne polycyclic aromatic
hydrocarbons, and childhood abuse are associated with aberrant
methylation of the insulin-like growth factor IGF2, the long-chain
acetyl-CoA synthetase ACSL3, and the hippocampal glucocorticoid
receptor NR3C1, respectively (Heijmans et al, 2008; McGowan
et al, 2009; Perera et al, 2009). Aberrant methylation of ACSL3 and
NR3C1 have in turn been associated with an increased risk of
childhood asthma and suicide, respectively (McGowan et al, 2009;
Perera et al, 2009).
Early age at smoking initiation is reported to increase the risk of
both lung and cervical cancer, independent of smoking duration or
intensity (Wiencke et al, 1990; Appleby et al, 2006). Such an
association is biologically plausible because lung tissues continue
to grow and develop into early adulthood, whereas the onset of
sexual activity in young women is followed by the extensive
remodelling of cervical epithelium, a process, which is accelerated
by tobacco smoking (Wiencke and Kelsey, 2002; Hwang et al,
2009). However, evidence directly linking early age of smoking
initiation to specific genetic, or epigenetic, changes is difficult to
adduce. Although cross-sectional surveys, restricted to patients
with cancer, have shown that the aberrant methylation of tumour
suppressor genes (TSG) is associated with various aspects
of smoking exposure, such surveys cannot distinguish those
epigenetic changes that are a consequence of the disease process
from those that are directly attributable to smoking (Kim et al,
2003; Marsit et al, 2005). More compelling evidence of smoking-
induced epigenetic changes is dependent upon demonstrating, in
disease-free individuals, that the onset of smoking precedes the
detection of such changes. Such evidence requires a longitudinal
study design. The accessibility of the cervix uteri, and the
acceptability of the sampling process, presents the opportunity
for making repeated observations, thus providing an ideal model
for the exploration of the determinants of epigenetic changes. We
have investigated the relationship between smoking initiation and
the first appearance of methylated forms of the TSG CDKN2A
(p16), in cervical cytological samples taken from a cohort of
young women who were recruited soon after they first had sexual
intercourse.
MATERIALS AND METHODS
The study design and characteristics of the study population have
been described elsewhere (Woodman et al, 2001). In brief, 2011
women aged 15–19 years were recruited from a single Brook
Advisory Centre (a family planning clinic) in Birmingham, UK,
between 1988 and 1992, and asked to re-attend at intervals of
6 months; follow-up ended on 31 August 1997. At recruitment, a
standardised interview questionnaire was used to construct
a detailed social, sexual, and behavioural risk-factor profile,
including smoking. Sexual and smoking histories were updated
at each follow-up visit. In addition, at each visit, two cervical
cytological samples were taken using the same Ayres spatula; the
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yfirst was used to prepare a smear for immediate cytological
evaluation; and the second was placed into 10ml of phosphate-
buffered saline and stored at  801C for subsequent virological
examination. All women in whom a cervical cytological abnorm-
ality was identified were immediately referred to a dedicated
research clinic for histological examination, irrespective of the
severity of that abnormality. Colposcopic and cytological surveil-
lance were maintained in these women, and treatment was
postponed, until there was histological evidence of high-grade
cervical intraepithelial neoplasia (CIN2 or CIN3), at which point
women left the study. The study was approved by the appropriate
Research Ethics Committee, and informed oral consent was
obtained from all women.
Study population
The study population for this analysis was drawn from the 1075
women who were cytologically normal and who tested negative for
human papillomavirus (HPV) DNA of any type in cervical samples
taken at study entry, and who had further follow-up (Figure 1).
From this cohort, we identified 97 women who first began to
smoke during follow-up. Of these, 60 women had one or more
consecutive samples immediately following smoking initiation
when they also tested negative for HPV DNA and were
cytologically normal. Excluded from further analyses were:
10 women in whom the last sample taken before smoking
initiation was unavailable, or not evaluable; three women in whom
this sample tested positive for methylated forms of CDKN2A; and
nine women in whom the sample taken while they were smoking
was unavailable, or not evaluable. The remaining 38 women
entered the analysis comparing the risk of CDKN2A methylation in
incident smokers with that in never-smokers, but only follow-up
time before the first detection of HPV DNA of any type, or of
cytological abnormality, in cervical samples, was included.
Assessment of smoking exposure and HPV status
Assessment of smoking exposure. Smoking histories were updated
at each follow-up visit. Smoking quantity was recorded as a
categorical variable, with categories; 0 cigarettes smoked per day,
1–9, 10–19, 20–29, 30–39, and 40 or more. Cumulative smoking
exposure was measured using pack-years, estimated as the
midpoint of each smoking-quantity category (with the final
category arbitrarily set to 45), multiplied by the length of the
interval during which this quantity applied, and accumulated over
the lifetime of the woman.
Assessment of HPV status. Cervical samples were tested for the
presence of HPV DNA using a general primer (GP5þ/GP6þ)-
mediated polymerase chain reaction (PCR) and further PCR tests
were performed with type-specific primers on samples, which were
HPV-positive, using methods previously described (Woodman
et al, 2001).
Assessment of outcome status (DNA methylation of
CDKN2A)
DNA extraction. For the present study, the remainder of the
stored sample was pelleted, and DNA isolated by digestion with
proteinase K, followed by standard phenol–chloroform extraction
and ethanol precipitation. The NanoDrop ND-100 Spectro-
photometer (Thermo Scientific, Wilmington, DE, USA) was used
to measure DNA concentration, according to the manufacturer’s
instructions.
Bisulphite modification. DNA (200ng) were isolated from each
cervical cytological sample, and bisulphite modified using the EZ
DNA Methylation-Gold Kit (Zymo Research, Irvine, CA, USA)
according to the manufacturer’s instructions. The converted DNA
was eluted in a final volume of 50ml.
Methylation-specific PCR. As the samples were taken from young
women with short smoking histories and were therefore likely to
contain only a small number of cells with methylated forms, we
elected to test for methylated forms of the CDKN2A gene using a
nested two-stage methylation-specific PCR method (Palmisano
et al, 2000). For the stage 1 PCR, 5ml of bisulphite-modified DNA
were amplified in a 25ml volume using 12.5ml of GoTaq Green
Mastermix (Promega UK Ltd, Southampton, UK), and 0.4mmoll
 1
of primer mix. The stage 1 primers recognise the bisulphite-
modified template but do not discriminate between methylated
and unmethylated alleles. Primer sequences used in this stage
were: forward 50-GAAGAAAGAGGAGGGGTTGG-30, and reverse
50-CTACAAACCCTCTACCCACC-30. Amplification was performed
using a P 2 Thermal Cycler (Thermo Scientific) with the follow-
ing cycle conditions: 951C for 10min, followed by 40 cycles of 951C
for 30s, 561C for 30s, 721C for 30s, and a final extension of 721C
for 10min. The stage 2 PCR was performed on 5ml of diluted stage
1 PCR product, using primers specific for methylated and
unmethylated template. Amplification was performed in a 25ml
volume, using 12.5ml of GoTaq Green Mastermix (Promega UK
Ltd) and 0.4mmoll
 1 of primer mix. Primer sequences used in this
stage were: forward unmethylated 50-TTATTAGAGGGTGGGGTG
GATTGT-30, reverse unmethylated 50-CAACCCCAAACCACAACC
ATAA-30, forward methylated 50-TTATTAGAGGGTGGGGCGGAT
CGC-30, and reverse methylated 50-GACCCCGAACCGCGACCGT
AA-30. For the stage 2 PCR, the annealing temperatures were
increased to 651C (unmethylated) and 701C (methylated), and all
cycling times were reduced to 15s. All stage 2 amplifications were
performed in duplicate. Stage 2 PCR products were analysed using
2% agarose gel electrophoresis and ethidium bromide staining
(Figure 2). Controls included CpGenome Universal methylated and
unmethylated (vial B) DNA (Millipore (UK) Ltd, Watford, UK).
Sensitivity for detecting methylated alleles in a background of
unmethylated alleles was determined by mixing DNA isolated from
the CpGenome Universal methylated control with DNA isolated
from the CpGenome Universal unmethylated control, to achieve
1075 women
(Normal smear and HPV-negative at study entry)
Never-smoker
n=631
Smoker or ex-smoker
n=444
First started to smoke during follow-up
n=97
60 women
with follow-up during which they were
HPV-negative and cytologically normal
Pre-smoking smear missing n=8
Pre-smoking smear non-evaluable n=2
Pre-smoking smear methylated n=3
Smoking smear missing n=3
Smoking smear non-evaluable n=6
38 women
Negative for CDKN2A methylation in pre-smoking smear
Abnormal smear or positive for HPV DNA
in next available smear n=37
Smoking status
at study entry
Smoking status
during follow-up
Figure 1 Flow diagram to show the selection of women for CDKN2A
methylation analysis.
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then subjected to bisulphite modification and subsequent analysis
by nested methylation-specific PCR. The sensitivity of the nested
methylation-specific PCR assay we used was 1:1000, similar to
that reported elsewhere (Cirincione et al, 2006). To exclude false
priming, that is, amplification of unmethylated alleles by the
methylated primers, a subset of methylated products were analysed
by direct sequencing: methylation of all CpGs within the CDKN2A
primer sites was observed in every case. A sample was considered
to be positive for CDKN2A methylation when a methylated band
was seen in both stage 2 PCR replicates using the methylated
primers; negative for CDKN2A methylation when only an
unmethylated band was detected; and non-evaluable when no
band was seen using either the methylated or the unmethylated
primers.
Statistical analysis
The matched analysis of the incidence of CDKN2A methylation was
undertaken using conditional logistic regression: confidence
intervals for odds ratios were calculated using parameter estimates
and their s.e.’s obtained from the model; statistical comparisons
were made using the likelihood ratio test. All tests of statistical
significance were conducted at the 5% two-sided significance level.
RESULTS
Of the 38 women who tested negative for CDKN2A methylation
in the sample taken immediately before they began to smoke,
eight tested positive for CDKN2A methylation following smoking
initiation; the median time to the first detection of CDKN2A
methylation in those who acquired CDKN2A methylation was 266
days (inter-quartile range from 178 to 382). Each of the 38 women
contributing to the incidence analysis was matched with two
randomly selected never-smokers (controls) on length of follow-up
(within 30 days); both groups were similar with respect to
demographic and sexual behaviour characteristics (Table 1). For
the eight women who first tested positive for methylated forms of
CDKN2A after smoking initiation, the follow-up period was
defined as the time interval between the date of the last
unmethylated sample taken before smoking initiation and the
date of the first sample to test positive for methylated forms of
CDKN2A during that smoking episode, that is, while the woman
continued to smoke. For the remaining 30 women who did not test
positive for methylated forms of CDKN2A after they started to
smoke, the follow-up period was defined as the time interval
between the date of the last unmethylated sample taken before
smoking initiation and the date of the last sample taken during
that smoking episode. The first and last matched samples from
each control were tested for the presence of methylated forms of
CDKN2A. Three controls were excluded from subsequent analyses
because of the presence of methylated forms of CDKN2A in the
first of their two samples (n¼2) or because one of the two samples
was not evaluable (n¼1). Of the remaining 73 controls who tested
negative for methylated forms of CDKN2A in their first sample,
five tested positive for these forms in their second sample.
Compared with never-smokers, women who first started to smoke
during follow-up had an increased risk of the acquisition of
methylated forms of CDKN2A (odds ratio¼3.67; 95% confidence
interval 1.09–12.33; w
2¼4.42; 1 degree of freedom; P¼0.04);
controlling for number of sexual partners had no effect.
DISCUSSION
Using the cervix uteri as a model, we have shown that smoking
increases the risk of acquiring methylated forms of CDKN2A,a
TSG, the epigenetic inactivation of which is strongly associated
with the pathogenesis of neoplasia at many sites (Herman et al,
1995; Merlo et al, 1995). Our longitudinal study design and our
unique study population (young women who had recently
embarked on sexual activity and who tested negative for HPV
DNA of any type and were cytologically free of disease) allowed us
to reveal, for the first time, the relationship between an incident
exposure (smoking initiation) and the subsequent appearance of
an epigenetic change (methylation of CDKN2A). Such opportu-
nities for demonstrating temporality in vivo come along rarely.
The number of women in our original cohort was substantial, but
Table 1 Baseline characteristics of women in the matched cohort study
Characteristic
Incident smokers
(n¼38)
Matched controls
(n¼76)
Mean age (years) 17.4 17.7
No. of sexual partners (%)
0 1 (3) 1 (1)
1 20 (53) 56 (74)
2 12 (32) 7 (9)
3 5 (13) 9 (12)
4 0 (0) 0 (0)
5 0 (0) 1 (1)
46 0 (0) 2 (3)
Mean no. of sexual partners 1.9 1.1
Age at first sexual intercourse (years) (%)
o13 0 (0) 1 (1)
14 4 (11) 3 (4)
15 5 (13) 8 (11)
16 12 (32) 31 (41)
17 10 (26) 19 (25)
18 7 (18) 9 (12)
19 0 (0) 4 (5)
Not applicable 0 (0) 1 (1)
Mean age at first sexual
intercourse (years)
16.3 16.5
Mean number of samples tested
(range)
2.5 (2–6) 2 (2–2)
12
150bp
151bp
11 12 13 14 15 16 17 18 19 20 H2Oa
150bp
151bp
3 4 5 6 7 8 9 10 UCB MC
M primers
M primers
U primers
U primers
H2O
Figure 2 Representative results of the stage 2 PCR using methylated
(M) and unmethylated (U) primers for the CDKN2A gene. Lanes 1–20,
cervical cytological samples taken from 20 women who were smokers. The
presence of a 150bp product using the methylated primers indicates that
the cytological sample was positive for CDKN2A methylation (samples 1, 2,
6, 9, 12, and 16). CpGenome Universal Unmethylated DNA (vial B) (UCB)
was used as a positive control for unmethylated DNA. CpGenome
Universal Methylated DNA (MC) was used as a positive control for
methylated DNA. H20a, water from both stages of the nested methylation-
specific PCR. H20, water from the stage 2 PCR only.
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women who tested negative for HPV DNA of any type and were
cytologically free of disease. Nevertheless by recruiting a cohort of
women who first began to smoke during follow-up, we were able to
show that this epigenetic change appeared soon after smoking
initiation. So soon after smoking initiation, in fact, that had our
analysis been restricted to women who were prevalent smokers at
baseline, we might have failed to detect such an association in a
longitudinal analysis in which observations were made at intervals
of approximately 6 months.
Our findings are consistent with those of a cross-sectional
study reporting a nonsignificant two-fold excess of methylated
forms of CDKN2A in normal cervical smears taken from smokers,
compared with those taken from non-smokers; the higher
prevalence of methylated forms of CDKN2A observed in our study
may be because we used nested methylation-specific PCR, a more
sensitive assay (Palmisano et al, 2000; Lea et al, 2004). Compared
with never-smokers, current smokers who are cancer-free, but not
necessarily disease-free, are also reported to have a higher
prevalence of methylated forms of the TSGs fragile histidine triad
(FHIT) and O-6-methylguanine-DNA methyltransferase (MGMT)
in bronchial lavages and plasma, respectively (Kim et al, 2004;
Belinsky et al, 2005).
In vitro studies in both untransformed and transformed cell
lines show that short-term exposure to nicotine, or to cigarette
smoke extract, is followed by changes in the expression of the
DNA methyltransferases DNMT1, DNMT3A, and DNMT3B. These
transcriptional changes have in turn been linked to the hyper-
methylation of FHIT, and to the demethylation of the oncogene
synuclein-gamma (SNCG) (Soma et al, 2006; Liu et al, 2007).
In murine models of cigarette smoke-induced lung cancer,
hypermethylation of the TSGs, death-associated protein kinase 1
(DAPK1) and the retinoic acid receptor beta (RARB), is seen at the
earliest histological stage of adenocarcinoma development (Pulling
et al, 2004; Vuillemenot et al, 2004).
Even allowing for possible inaccuracy in self-reporting, smoking
behaviour is unlikely to account for all cases of CDKN2A
methylation occurring in this cohort. In women who never
smoked, epigenetic changes may be explained by other, as yet
undefined, risk factors. For example, levels of airborne benzene
have been associated with the methylation of p15 (CDKN1B)i n
healthy individuals (Bollati et al, 2007; Baccarelli et al, 2009).
Meta-analyses suggest that smoking cessation interventions
have little effect on the behaviour of adolescents and young adults
(Grimshaw and Stanton, 2006; Myung et al, 2009). Adolescent
smokers largely discount distant health risks and consider people
their own age invulnerable to the adverse effects of smoking
(Balch, 1998; McVea et al, 2009). It has been argued that new
information on the more immediate health effects of smoking is
needed to challenge these disengagement beliefs (Kleinjan et al,
2009). This study provides such information.
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